Ardelyx (ARDX)
(Delayed Data from NSDQ)
$5.99 USD
-0.05 (-0.83%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $6.00 +0.01 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.99 USD
-0.05 (-0.83%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $6.00 +0.01 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Zacks News
Aerie Pharmaceuticals (AERI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Aerie (AERI) delivered earnings and revenue surprises of 260.29% and 272.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Ardelyx (ARDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Implied Volatility Surging for Ardelyx (ARDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Is a Surprise Coming for Ardelyx (ARDX) This Earnings Season?
by Zacks Equity Research
Ardelyx (ARDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Editas (EDIT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) third-quarter earnings call, investor focus will likely be on the company's progress with the development of its lead pipeline candidate, EDIT-101.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.
Is the Options Market Predicting a Spike in Ardelyx (ARDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -25.00% and 19.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA
by Zacks Equity Research
The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -6.25% and 498.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ardelyx (ARDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Ardelyx (ARDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Ardelyx (ARDX) Stock Jumps 6.8%: Will It Continue to Soar?
by Zacks Equity Research
Ardelyx (ARDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -23.08% and -3.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Ardelyx (ARDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -3.70% and 63.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Ardelyx Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Ardelyx
Ardelyx (ARDX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why Momentum Investors Will Love Ardelyx (ARDX)
by Zacks Equity Research
Does Ardelyx (ARDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 221.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.